Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety, Tolerability, and PK of Lucerastat in Healthy Volunteers
NCT02944474Phase 1Completed
- Sponsor
- Idorsia
- Start
- Dec 2003
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lucerastat in Fabry disease (FD) (5 arms), sponsored by Idorsia. Primary endpoints: Maximum Plasma Concentration (Cmax) for Dose Proportionality at Day 7, Area Under the Concentration-Time Curve (AUC) for Dose Proportionality at Day 7 and 7 more. Started Dec 2003; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT02944474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944474.